File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Elevated levels of transforming growth factor-beta1 in serum of patients with stable bronchiectasis

TitleElevated levels of transforming growth factor-beta1 in serum of patients with stable bronchiectasis
Authors
Issue Date2004
PublisherWiley-Blackwell Publishing Asia
Citation
The 9th Congress of the Asian Pacific Society of Respirology, Hong Kong, 10-13 December 2004. In Respirology, 2004, v. 9 n. S3, p. A134 Abstract no. 198 How to Cite?
AbstractBronchiectasis is a condition, where serious and repeated infections and abnormal development of the lung result in permanent damage to the airways. Transforming growth factor-b1 (TGF-b1) is a major fibrogenic cytokine, the expression of which is increased in the lungs or bronchoalveolar lavage fluid of patients with inflammatory lung diseases. However, little is known on the expression of TGF-b1 levels in bronchiectasis. We measured the serum TGF-b1 concentrations in 95 patients with stable bronchiectasis (63 women; mean ± SD age, 58.9 ± 14.1 years) and 68 control subjects (23 women; 48.9 ± 12.8 years) by ELISA, and correlated these with clinical parameters. The serum TGF-b1 levels were significantly higher in bronchiectatic patients compared with control subjects (mean ± SEM, 2710.7 ± 197.4 pg/ml vs 1649.2 ± 124.2 pg/ml; P < 0.001). Smoking controls tended to have a higher serum TGF-b1 level but no differences were found between nonsmokers and smokers, with or without Pseudomonas aeruginosa infection in bronchiectatic patients. There was no correlation between serum TGF-b1 levels with FEV1 (% predicted), FVC (% predicted), 24 h sputum volume, number of bronchiectatic lung lobes and white blood cell (WBC) count (P > 0.05). In conclusion, systemic TGF-b1 appears to be elevated in bronchiectasis independent of other clinical parameters, and the level of serum TGF-b1 may be used to predict the presence or absence of the disease. Further studies on the potential mechanisms and pathogenesis implications of this elevation should be pursued in future. (Supported by a University of Hong Kong, URC/CRCG Research Grant)
Persistent Identifierhttp://hdl.handle.net/10722/101080
ISSN
2015 Impact Factor: 3.078
2015 SCImago Journal Rankings: 1.157

 

DC FieldValueLanguage
dc.contributor.authorMak, JCWen_HK
dc.contributor.authorHo, SPen_HK
dc.contributor.authorLeung, YHen_HK
dc.contributor.authorHo, PLen_HK
dc.contributor.authorOoi, CGCen_HK
dc.contributor.authorYan, CPKen_HK
dc.contributor.authorKo, KWen_HK
dc.contributor.authorIp, MSMen_HK
dc.contributor.authorLam, WKen_HK
dc.contributor.authorTsang, KWTen_HK
dc.date.accessioned2010-09-25T19:35:10Z-
dc.date.available2010-09-25T19:35:10Z-
dc.date.issued2004en_HK
dc.identifier.citationThe 9th Congress of the Asian Pacific Society of Respirology, Hong Kong, 10-13 December 2004. In Respirology, 2004, v. 9 n. S3, p. A134 Abstract no. 198en_HK
dc.identifier.issn1323-7799-
dc.identifier.urihttp://hdl.handle.net/10722/101080-
dc.description.abstractBronchiectasis is a condition, where serious and repeated infections and abnormal development of the lung result in permanent damage to the airways. Transforming growth factor-b1 (TGF-b1) is a major fibrogenic cytokine, the expression of which is increased in the lungs or bronchoalveolar lavage fluid of patients with inflammatory lung diseases. However, little is known on the expression of TGF-b1 levels in bronchiectasis. We measured the serum TGF-b1 concentrations in 95 patients with stable bronchiectasis (63 women; mean ± SD age, 58.9 ± 14.1 years) and 68 control subjects (23 women; 48.9 ± 12.8 years) by ELISA, and correlated these with clinical parameters. The serum TGF-b1 levels were significantly higher in bronchiectatic patients compared with control subjects (mean ± SEM, 2710.7 ± 197.4 pg/ml vs 1649.2 ± 124.2 pg/ml; P < 0.001). Smoking controls tended to have a higher serum TGF-b1 level but no differences were found between nonsmokers and smokers, with or without Pseudomonas aeruginosa infection in bronchiectatic patients. There was no correlation between serum TGF-b1 levels with FEV1 (% predicted), FVC (% predicted), 24 h sputum volume, number of bronchiectatic lung lobes and white blood cell (WBC) count (P > 0.05). In conclusion, systemic TGF-b1 appears to be elevated in bronchiectasis independent of other clinical parameters, and the level of serum TGF-b1 may be used to predict the presence or absence of the disease. Further studies on the potential mechanisms and pathogenesis implications of this elevation should be pursued in future. (Supported by a University of Hong Kong, URC/CRCG Research Grant)-
dc.languageengen_HK
dc.publisherWiley-Blackwell Publishing Asia-
dc.relation.ispartofRespirologyen_HK
dc.titleElevated levels of transforming growth factor-beta1 in serum of patients with stable bronchiectasisen_HK
dc.typeConference_Paperen_HK
dc.identifier.emailMak, JCW: judymak@HKUCC.hku.hken_HK
dc.identifier.emailLeung, YH: yhleung@HKUCC.hku.hken_HK
dc.identifier.emailHo, PL: plho@hkucc.hku.hken_HK
dc.identifier.emailOoi, CGC: cgcooi@hkucc.hku.hken_HK
dc.identifier.emailYan, CPK: cpkyan@HKUSUA.hku.hken_HK
dc.identifier.emailIp, MSM: msmip@hku.hken_HK
dc.identifier.emailLam, WK: lamwk@hku.hken_HK
dc.identifier.emailTsang, KWT: kwttsang@hku.hken_HK
dc.identifier.authorityMak, JCW=rp00352en_HK
dc.identifier.authorityHo, PL=rp00406en_HK
dc.identifier.authorityIp, MSM=rp00347en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1440-1843.2004.00673.x-
dc.identifier.hkuros98149en_HK
dc.identifier.volume9en_HK
dc.identifier.issueS3en_HK
dc.identifier.spageA134en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats